Myriad Genetics

MYGN

Market cap $652M

6.88 USD

-0.11

1.57%

At close Updated Dec 16, 4:00 PM EST

Pre-market

After hours

6.88

0.00

1 day

-1.57%

5 days

-6.65%

1 month

3.3%

3 months

-8.27%

6 months

39.84%

Year to date

-49.04%

1 year

-51.27%

5 years

-61.41%

10 years

-84.31%

About: Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Employees: 2,700

Healthcare Diagnostics & Research